{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:36:36Z","timestamp":1773678996084,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009858","name":"Gabrielle\u2019s Angel Foundation for Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tamarind Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00520-016-3441-6","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T18:33:33Z","timestamp":1478716413000},"page":"701-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-7800","authenticated-orcid":false,"given":"Stephen","family":"Sands","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena J.","family":"Ladas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiko","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah Hughes","family":"Ndao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amie","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda T.","family":"Vahdat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Glade","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,9]]},"reference":[{"key":"3441_CR1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","volume":"29","author":"CEM Gidding","year":"1999","unstructured":"Gidding CEM, Kellie SJ, Kamps WA, de Graaf SSN (1999) Vincristine revisited. Crit Rev Oncol Hematol 29:267\u2013287","journal-title":"Crit Rev Oncol Hematol"},{"key":"3441_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253\u2013265","journal-title":"Nat Rev Cancer"},{"key":"3441_CR3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF03259853","volume":"1","author":"SS Legha","year":"1986","unstructured":"Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Medical toxicology 1:421\u2013427","journal-title":"Medical toxicology"},{"key":"3441_CR4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/NCC.0b013e3181c989a3","volume":"33","author":"EML Smith","year":"2010","unstructured":"Smith EML, Cohen JA, Pett MA, Beck SL (2010) The reliability and validity of a modified Total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving Taxanes and Platinums. Cancer Nurs 33:173\u2013183","journal-title":"Cancer Nurs"},{"key":"3441_CR5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00520-012-1591-8","volume":"21","author":"LS Gilchrist","year":"2013","unstructured":"Gilchrist LS, Tanner L (2013) The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 21:847\u2013856","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"key":"3441_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00520-013-1981-6","volume":"22","author":"LS Gilchrist","year":"2014","unstructured":"Gilchrist LS, Marais L, Tanner L (2014) Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 22:359\u2013366","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"3441_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11845-013-0971-5","volume":"183","author":"S Vasquez","year":"2014","unstructured":"Vasquez S, Guidon M, McHugh E, Lennon O, Grogan L, Breathnach OS (2014) Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice. Ir J Med Sci 183:53\u201358","journal-title":"Ir J Med Sci"},{"key":"3441_CR8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf B, Crews KR, Lew G et al (2015) Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815\u2013823","journal-title":"JAMA"},{"key":"3441_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pain.2011.10.028","volume":"153","author":"MI Bennett","year":"2012","unstructured":"Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S (2012) Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153:359\u2013365","journal-title":"Pain"},{"key":"3441_CR10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","volume":"14","author":"S Ramchandren","year":"2009","unstructured":"Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst: JPNS 14:184\u2013189","journal-title":"J Peripher Nerv Syst: JPNS"},{"key":"3441_CR11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0883073813491829","volume":"29","author":"P Jain","year":"2014","unstructured":"Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM (2014) Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol 29:932\u2013937","journal-title":"J Child Neurol"},{"key":"3441_CR12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.apmr.2013.03.009","volume":"94","author":"KK Ness","year":"2013","unstructured":"Ness KK, Jones KE, Smith WA et al (2013) Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude lifetime cohort study. Arch Phys Med Rehab 94:1451\u20131457","journal-title":"Arch Phys Med Rehab"},{"key":"3441_CR13","first-page":"471","volume-title":"Progress in molecular biology and translational science","author":"JC Fehrenbacher","year":"2015","unstructured":"Fehrenbacher JC (2015) Chemotherapy-induced peripheral neuropathy. In: Theodore JP, Gregory D (eds) Progress in molecular biology and translational science. New York, Academic Press, pp. 471\u2013508"},{"key":"3441_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.mt.6300019","volume":"15","author":"R Kirchmair","year":"2007","unstructured":"Kirchmair R, Tietz AB, Panagiotou E et al (2007) Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Molecular therapy. J Am Soc Gene Ther 15:69\u201375","journal-title":"J Am Soc Gene Ther"},{"key":"3441_CR15","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.104.470849","volume":"111","author":"R Kirchmair","year":"2005","unstructured":"Kirchmair R, Walter DH, Ii M et al (2005) Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 111:2662\u20132670","journal-title":"Circulation"},{"key":"3441_CR16","first-page":"245","volume":"7","author":"DV Jackson Jr","year":"1984","unstructured":"Jackson DV Jr, Rosenbaum DL, Carlisle LJ, Long TR, Wells HB, Spurr CL (1984) Glutamic acid modification of vincristine toxicity. Cancer Biochem Biophys 7:245\u2013252","journal-title":"Cancer Biochem Biophys"},{"key":"3441_CR17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(25)20981-8","volume":"279","author":"FM Boyle","year":"1996","unstructured":"Boyle FM, Wheeler HR, Shenfield GM (1996) Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 279:410\u2013415","journal-title":"J Pharmacol Exp Ther"},{"key":"3441_CR18","first-page":"1192","volume":"7","author":"L Vahdat","year":"2001","unstructured":"Vahdat L, Papadopoulos K, Lange D et al (2001) Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res: Off J Am Assoc Cancer Res 7:1192\u20131197","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"3441_CR19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clon.2004.11.014","volume":"17","author":"MD Stubblefield","year":"2005","unstructured":"Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL (2005) Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol 17:271\u2013276","journal-title":"Clin Oncol"},{"key":"3441_CR20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","volume":"12","author":"WS Wang","year":"2007","unstructured":"Wang WS, Lin JK, Lin TC et al (2007) Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12:312\u2013319","journal-title":"Oncologist"},{"key":"3441_CR21","first-page":"90","volume":"6","author":"S De Santis","year":"2000","unstructured":"De Santis S, Pace A, Bove L et al (2000) Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res: Off J Am Assoc Cancer Res 6:90\u201395","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"3441_CR22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1016-8478(23)13316-4","volume":"7","author":"BJ Gwag","year":"1997","unstructured":"Gwag BJ, Sessler FM, Robine V, Springer JE (1997) Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus. Mol Cells 7:425\u2013430","journal-title":"Mol Cells"},{"key":"3441_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1006124917643","volume":"41","author":"FM Boyle","year":"1999","unstructured":"Boyle FM, Wheeler HR, Shenfield GM (1999) Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neuro-Oncol 41:107\u2013116","journal-title":"J Neuro-Oncol"},{"key":"3441_CR24","unstructured":"Cancer therapy evaluation program common terminology criteria for adverse events, version 3.0 In: DCTD N, NIH, DHHS ed. March 31, 2003 ed. ( http:\/\/ctep.cancer.gov ) Publish Date: August 9, 2006"},{"key":"3441_CR25","volume-title":"Symbol digit modalities test","author":"A Smith","year":"1991","unstructured":"Smith A (1991) Symbol digit modalities test. Western Psychological Corporation, Los Angeles"},{"key":"3441_CR26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2466\/pms.1988.66.2.503","volume":"66","author":"JR Reddon","year":"1988","unstructured":"Reddon JR, Gill DM, Gauk SE, Maerz MD (1988) Purdue Pegboard: test-retest estimates. Percept Mot Skills 66:503\u2013506","journal-title":"Percept Mot Skills"},{"key":"3441_CR27","volume-title":"Clinical neuropsychology: current status and applications","author":"R Reitan","year":"1974","unstructured":"Reitan R, Davison L (1974) Clinical neuropsychology: current status and applications. Washington, D.C, V.H. Winston"},{"key":"3441_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS (2001) PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 39:800\u2013812","journal-title":"Med Care"},{"key":"3441_CR29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","volume":"3","author":"JW Varni","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D (2003) The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr: Off J Ambul Pediatr Assoc 3:329\u2013341","journal-title":"Ambul Pediatr: Off J Ambul Pediatr Assoc"},{"key":"3441_CR30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/ejpn.1999.0310","volume":"4","author":"HA Reinders-Messelink","year":"2000","unstructured":"Reinders-Messelink HA, Van Weerden TW, Fock JM et al (2000) Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol: EJPN: Off J Eur Paediatr Neurol Soc 4:225\u2013233","journal-title":"Eur J Paediatr Neurol: EJPN: Off J Eur Paediatr Neurol Soc"},{"key":"3441_CR31","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","volume":"53","author":"DR Cornblath","year":"1999","unstructured":"Cornblath DR, Chaudhry V, Carter K et al (1999) Total neuropathy score: validation and reliability study. Neurology 53:1660\u20131664","journal-title":"Neurology"},{"key":"3441_CR32","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","volume":"36","author":"EM Lavoie Smith","year":"2013","unstructured":"Lavoie Smith EM, Li L, Hutchinson RJ et al (2013) Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 36:E49\u2013E60","journal-title":"Cancer Nurs"},{"issue":"1","key":"3441_CR33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jns.12114","volume":"20","author":"EM Lavoie Smith","year":"2015","unstructured":"Lavoie Smith EM, Li L, Chiang C et al (2015) Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst 20(1):37\u201346","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"3441_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","volume":"56","author":"A Egbelakin","year":"2011","unstructured":"Egbelakin A, Ferguson MJ, MacGill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361\u2013367","journal-title":"Pediatr Blood Cancer"},{"key":"3441_CR35","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/pbc.25384","volume":"62","author":"SM Bradfield","year":"2015","unstructured":"Bradfield SM, Sandler E, Geller T, Tamura RN, Krischer JP (2015) Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer. Pediatr Blood Cancer 62:1004\u20131010","journal-title":"Pediatr Blood Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3441-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3441-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:58:58Z","timestamp":1749715138000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3441-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3441"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3441-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,9]]}}}